Cure8 research brief
Preclinical results suggest a fermented yak milk–derived probiotic strain may protect against colitis in mice by improving barrier function, lowering inflammatory cytokines, and changing the gut microbiome—mechanisms relevant to IBD research and potential future therapies.
Researchers, clinicians, and patients interested in probiotics, microbiome interventions, and preclinical IBD research.
This mouse study tested a probiotic strain (Lacticaseibacillus paracasei CD12-1) derived from fermented yak milk for prevention of colitis caused by dextran sulfate sodium (DSS).
The authors report that CD12-1—especially at a low dose—reduced colon damage, improved markers of barrier integrity (ZO-1, Occludin), lowered pro-inflammatory cytokines (IL‑1β, IL‑6, TNF‑α), increased IL‑10, raised acetate and butyrate levels, and altered gut microbiota composition.
The findings are from a controlled animal model (DSS-induced colitis in mice), not humans. While results suggest mechanisms (barrier protection, anti-inflammatory effects, shifts in short‑chain fatty acids and microbial taxa), they do not demonstrate safety or efficacy in people with ulcerative colitis or IBD.
If you are a patient considering probiotics, this study adds to preclinical evidence but does not substitute for clinical trial data or medical advice. Talk with your IBD clinician before starting any new supplement.
Animal-model findings do not equal clinical benefit in people; this study is a preclinical, mechanistic report and does not establish safety or effectiveness for patients.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Science and Technology Project of the Department of Agriculture and Rural Affairs of Gansu Province, award GNKJ-2026-24; Gansu Agricultural University, award YB2025002; award YB2025002; Gansu Province University Graduate “Innovation Star” Project, award 2026CXZX-779; Science and Technology Project of Gansu Province, award 26ZDNA010
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study identifies a plant-derived polysaccharide (from the stem of Dendrobium huoshanense) that reduced inflammation and tissue injury in a mouse model of ulcerative colitis and points to GLP-1 signaling as a likely...
The study identifies a plant extract that reduced colitis-like injury in mice and altered gut microbes and intestinal barrier markers, which could inform future preclinical work. For people with IBD, this is early-stage...
The study identifies a fungal β-glucan that reduced inflammation and altered the gut microbiome and short-chain fatty acids in a mouse model of ulcerative colitis, which could inform future nutritional or therapeutic...
